Online citations, reference lists, and bibliographies.
← Back to Search

A Dimethoxynaphthalene Derivative (RS‐43179 Gel) Compared With 0.025% Fluocinolone Acetonide Gel In The Treatment Of Psoriasis

A. Lassus, S. Forsstrom
Published 1985 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Thirty patients were entered into a double‐blind trial comparing a dimethoxynaphthalene derivative (RS‐43179 gel) and fluocinolone acetonide (Synalar® gel) in the treatment of psoriasis. the two preparations were applied three times daily for 4 weeks, and the patients were assessed at weeks 1, 2, 3, 4, 7 and 9. No significant differences between the two preparations could be detected. By the end of the 4‐week treatment period, the number of patients showing a ‘Good, Excellent or Clear’ therapeutic response was 25 out of 28 after RS‐43179 treatment and 26 out of 28 after Synalar® treatment. Four patients experienced irritation on the side treated with RS‐43179. IN two of these patients the reaction was severe and the treatment was discontinued, but in the other two patients, the local irritation was only moderate. No other adverse reactions were seen.
This paper references



This paper is referenced by
10.1007/BF01967296
Effect of a 5-lipoxygenase (5-LO)/cyclooxygenase (CO) inhibitor, WY-47, 288, on cutaneous models of inflammation
R. Carlson (2005)
10.1016/S0140-6736(88)91181-6
A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF FISH OIL IN PSORIASIS
S. B. Bittiner (1988)
10.1001/ARCHDERM.1989.01670140087017
Assessment of disease progress in psoriasis.
R. Marks (1989)
10.1016/S0738-081X(99)00106-6
Psoriasis, lichen planus, and disorders of keratinization: unapproved treatments or indications.
G. Capella (2000)
10.1016/S0079-6468(08)70004-3
5-lipoxygenase inhibitors and their anti-inflammatory activities.
D. Batt (1992)
10.1111/1523-1747.EP12469865
Leukotriene B4 formation during human neutrophil keratinocyte interactions: evidence for transformation of leukotriene A4 by putative keratinocyte leukotriene A4 hydrolase.
L. Iversen (1993)
10.1007/978-1-4684-7938-6_21
Inhibitors of leukotriene action : potential use in asthma, inflammatory bowel disease, and cutaneous inflammation
A. Welton (1989)
10.1016/0378-5173(87)90074-3
Non-steroidal anti-psoriatic prodrugs. Hydrolysis and aminolysis of naphthyl esters in aqueous solution
M. F. Powell (1987)
10.3109/09546639409084542
Topical non-steroidal anti-inflammatory drugs: a review of their use and toxicity
Sm Halpern (1994)
10.1016/0163-7258(90)90035-Z
Leukotrienes and inflammation.
S. Brain (1990)
10.1016/S0223-5234(98)80022-6
6-Amino-2,4-lutidine carboxamides: α-aminoamide derivatives as systemic and topical inflammation inhibitors
M. Duflos (1998)
10.1111/1523-1747.EP12873300
Pharmacologic and clinical effects of lonapalene (RS 43179), a 5-lipoxygenase inhibitor, in psoriasis.
A. Black (1990)
10.1016/0005-2760(88)90207-X
Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models.
E. Ku (1988)
10.1023/A:1015803226249
Release of Lonapalene from Two-Phase Emulsion-Type Ointment Systems
J. T. Ong (2004)
10.3109/09546638909086678
5-aminosalieylie acid in a cream base improves psoriasis. A double-blind study
T. Menné (1989)
10.1038/JID.1989.35
Cutaneous pharmacology: perspectives on the growth of investigation of mediators of inflammation.
R. Camp (1989)
10.1111/j.1365-2133.1988.tb05364.x
The clinical and pharmacological effect of lonapalene (RS‐43179), a 5‐lipoxygenase inhibitor, applied topically in psoriasis
A. Black (1988)
10.1007/978-3-642-74054-1_23
Non-steroidal Anti-inflammatory Agents and the Skin
M. Greaves (1989)
10.1001/ARCHDERM.1990.01670280071013
Sulfasalazine improves psoriasis. A double-blind analysis.
A. Gupta (1990)
10.1002/DDR.430130206
Psoriasis: Hyperproliferative/inflammatory skin disorder
V. Ziboh (1988)
10.1016/0952-3278(95)90090-X
Lipid mediators, free fatty acids and psoriasis.
F. Grimminger (1995)
10.1177/030006059001800109
Effects of Dietary Supplementation with Polyunsaturated Ethyl Ester Lipids (Angiosan®) in Patients with Psoriasis and Psoriatic Arthritis
A. Lassus (1990)
10.1001/ARCHDERM.1986.01660230069013
Effects of dietary supplementation of fish oil on neutrophil and epidermal fatty acids. Modulation of clinical course of psoriatic subjects.
V. Ziboh (1986)
10.1007/978-1-4615-2071-9_5
Omega-3s and Immune/Inflammatory Responses
J. Nettleton (1995)
10.1007/BF01964714
Histamine release from cord basophils
H. Nolte (2005)
10.3109/09546639609089562
What is new in the treatment of psoriasis
P. Kerkhof (1996)
10.1177/030006059101900207
A Double-Blind Study Comparing Oleum Horwathiensis with Placebo in the Treatment of Psoriasis
A. Lassus (1991)
10.1007/BF01966310
Biochemical and pharmacological properties of a new topical anti-inflammatory compound, 9-phenylnonanohydroxamic acid (BMY 30094)
K. Tramposch (2005)
10.1007/BF00184491
A double-blind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute, extended guttate psoriasis
F. Grimminger (2004)
10.1016/S0190-9622(87)70098-X
Pharmacology and significance of nonsteroidal anti-inflammatory drugs in the treatment of skin diseases.
M. Greaves (1987)
10.1007/978-94-009-1253-3_5
Novel eicosanoid inhibitors
L. Marshall (1989)
10.1016/0923-1811(90)90591-Z
Influence of eicosanoids on fibroblast chemotaxis and protein synthesis in vitro.
G. Rieger (1990)
See more
Semantic Scholar Logo Some data provided by SemanticScholar